Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate Cancer
The clinical study of PSMA-targeted CAR-T cells is positioned in a competitive landscape focused on advanced therapies for castration-resistant prostate cancer (CRPC). Given the high unmet medical need in this patient population, successful outcomes could lead to significant market opportunities, particularly as current treatment options are limited and often ineffective. The trial is sponsored by The Affiliated Hospital of Xuzhou Medical University, indicating potential for collaboration with academic institutions and access to innovative research capabilities. The study's focus on safety and efficacy will be critical for attracting interest from larger biopharma companies for potential partnerships or acquisitions. The trial's recruitment status is active, which is favorable for timely data generation and market entry.
Indication: Immunotherapy
Modality: cell therapy
Target: Prostate Specific Membrane Antigen (PSMA) targeted CAR-T cells
Sponsor: The Affiliated Hospital of Xuzhou Medical University
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Prostate Specific Membrane Antigen (PSMA) targeted CAR-T cells
View original source fields
Condition raw: Immunotherapy
Condition normalized: Immunotherapy
Modality raw: cell therapy
Modality normalized: cell therapy
Target raw: Prostate Specific Membrane Antigen (PSMA) targeted CAR-T cells
Target normalized: Prostate Specific Membrane Antigen (PSMA) targeted CAR-T cells